130 related articles for article (PubMed ID: 16381621)
1. Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
Clin Breast Cancer; 2005 Dec; 6(5):380-4. PubMed ID: 16381621
[No Abstract] [Full Text] [Related]
2. Herceptin and chemotherapy combination active in advanced breast cancer.
Cancer Biol Ther; 2004 Jun; 3(6):489. PubMed ID: 15717405
[No Abstract] [Full Text] [Related]
3. [Metastatic breast cancer--new methods of treatment].
Rack B; Heinemann V; Schindlbeck C; Walther J; Salat C; Sommer H
MMW Fortschr Med; 2008 Jan; 150(1-2):34-6. PubMed ID: 18300641
[No Abstract] [Full Text] [Related]
4. [Optimal chemotherapy for advanced and recurrent breast cancer patients].
Masuda N
Nihon Rinsho; 2007 Jun; 65 Suppl 6():523-9. PubMed ID: 17682205
[No Abstract] [Full Text] [Related]
5. Neoadjuvant combination for stage II-III breast cancer.
Bagchi S
Lancet Oncol; 2007 Jul; 8(7):579. PubMed ID: 17668486
[No Abstract] [Full Text] [Related]
6. HERe-2 stay: the continuing importance of translational research in breast cancer.
Sledge GW
J Natl Cancer Inst; 2004 May; 96(10):725-7. PubMed ID: 15150294
[No Abstract] [Full Text] [Related]
7. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
8. [Role of taxanes in treatment of breast cancer].
Gorbunova VA; Besova NS
Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
[No Abstract] [Full Text] [Related]
9. [Docetaxel (Taxotere) in combination with trastuzumab (Herceptin)].
Ficorella C
Tumori; 2001; 87(1 Suppl 2):S10-8. PubMed ID: 11357872
[No Abstract] [Full Text] [Related]
10. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
11. A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).
Moulder SL; Arteaga CL
Clin Breast Cancer; 2003 Jun; 4(2):142-5. PubMed ID: 12864943
[No Abstract] [Full Text] [Related]
12. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Bullock K; Blackwell K
Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
15. [Combined chemotherapy with molecular-targeted agent for breast cancer].
Ito Y; Miura H
Gan To Kagaku Ryoho; 2008 May; 35(5):731-6. PubMed ID: 18487908
[TBL] [Abstract][Full Text] [Related]
16. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Slamon D; Pegram M
Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
Valero V; Forbes J; Pegram MD; Pienkowski T; Eiermann W; von Minckwitz G; Roche H; Martin M; Crown J; Mackey JR; Fumoleau P; Rolski J; Mrsic-Krmpotic Z; Jagiello-Gruszfeld A; Riva A; Buyse M; Taupin H; Sauter G; Press MF; Slamon DJ
J Clin Oncol; 2011 Jan; 29(2):149-56. PubMed ID: 21115860
[TBL] [Abstract][Full Text] [Related]
18. The platinum agents: a role in breast cancer treatment?
Crown JP
Semin Oncol; 2001 Feb; 28(1 Suppl 3):28-37. PubMed ID: 11301372
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
Venturini M; Bighin C; Monfardini S; Cappuzzo F; Olmeo N; Durando A; Puglisi F; Nicoletto O; Lambiase A; Del Mastro L
Breast Cancer Res Treat; 2006 Jan; 95(1):45-53. PubMed ID: 16267615
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease.
Jara Sánchez C; Olier Gárate C; García-Donas Jiménez J; Peñalver Párraga J
Ann Oncol; 2009 Sep; 20(9):1607-1608. PubMed ID: 19633054
[No Abstract] [Full Text] [Related]
[Next] [New Search]
